Dermatotoxicology

I: Concepts  1. Pharmacogenetics and dermatology  2. Hormesis and dermatology  3.Toward an evidence-based dermatotoxicology  4. How to improve skin notation  5. Skin ion channels in health and disease  II: Systemic Toxicity  6. Systemic toxicity  7. Chemical respiratory allergy: opportunities for hazard identification and characterization  8. Nephrotoxicity of organic solvents from skin exposure  9. Mechanisms in cutaneous drug hypersensitivity reactions  10. Systemic allergic (contact) dermatitis  III: Local  Toxicity  11. Immunological mechanisms in irritant and allergic contact dermatitis  12. Allergic contact dermatitis: elicitation thresholds of potent allergens in humans  13. Photoirritation  14. Contact urticaria syndrome  IV:  Compounds  15. Percutaneous penetration enhancers: overview  16. Chemical warfare agents  17. Allergic contact dermatitis from ophthalmics  18. Textiles and human skin, microclimate, and cutaneous reactions: overview  19. Identifying the source of textile-dye allergic contact dermatitis: a guideline   20. Trichloroethylene dermatotoxicology: an update  21. Chemical agents that cause depigmentation  22. Hydroxychloroquine-induced retinopathy  23. Factors influencing applied amount of topical preparations  24. Immune reactions to copper  25. Sodium lauryl sulfate  26. Water: is it an irritant? 27. In vivo human transfer of topical bioactive drugs among individuals: estradiol and testosterone 28. Depigmentation changes as a result of arsenic exposure  V: Susceptibility of Different Populations  29. Gender and pharmacokinetics  30. Dermatological drug usage in the elderly  31. Sensitive skin: A valid syndrome of multiple origins  32. Dermatotoxicology of the vulva  33. Human scalp irritation related to arm and back  34. Functional map and age-related differences in human faces: nonimmunologic contact urticaria induced by hexyl nicotinate  35. Adhesive tape stripping reveals differences in stratum corneum cohesion between Caucasians, Blacks and Hispanics as a function of age  VI: Methods  36. Animal, human, and in vitro test methods for predicting skin irritation  37. Physiologically based pharmacokinetic modelling of dermal absorption  38. In vitro approaches to assessment of skin irritation and phototoxicity of topically applied materials  39. The local lymph node assay  40. Utilization of irritation data in local lymph node assay  41. Failure of standard test batteries for detection of genotoxic activity of some chemicals used in dermatological and cosmetic products  42. Determination of chromium and nickel allergy, sensitization, and toxicity by cellular in vitro methods  43. Methods for in vitro skin metabolism  44. In vitro model for decontamination of human skin: formaldehyde  45. Percutaneous absorption of hazardous substances from soil and water  46. Stratum corneum tape stripping method: an update   47. The diagnostic value of patch testing  48. Diagnostic tests in dermatology: patch and photopatch testing and contact urticaria  49. Photoirritation (phototoxicity or phototoxic dermatitis)  50. Significance of methyl mercury hair analysis: mercury biomonitoring in human scalp/nude mouse model  51. Use of modified forearm controlled application text to evaluate skin irritation of lotion formulations  52. Evaluating mechanical and chemical irritation using the behind-the-knee test: a review  53. Tests for sensitive skin  54. Dermatotoxicity of specialized epithelia: adapting cutaneous test methods to assess topical effects on the vulva  55. Biomarkers associated with severe cutaneous adverse reactions  VII: Treatment  56. Decreasing allergic contact dermatitis frequency through dermatotoxicologic and epidermic-based intervention 57. The importance of the skin decontamination wash-in effect  58. Water decontamination of chemical skin and eye splashes: a critical review  59. Irritant and allergic contact dermatitis treatment  60. Anti-irritants: myth or reality? An overview  VIII: Regulatory Aspects and Guidelines  61. Validation and regulatory acceptance of dermatotoxicology methods: recent progress and the role of NICEATM and ICCVAM  62. Safety and efficacy information in drug inserts for topical prescription medications  63. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs  64. OECD guidelines for testing of chemicals  65. Dermatologic drugs withdrawn by the FDA for safety reasons